OBJECTIVES The aim of this study was to determine whether presentation, risk assessment, testing choices, and results differ by sex in stable symptomatic outpatients with suspected coronary artery disease (CAD).
C ardiovascular disease is the leading cause of death and disability in women in the United States, yet it remains a diagnostic challenge (1) . Most studies that report sex differences in presenting symptoms and risk factor burden have examined populations with acute chest pain, acute coronary syndrome (ACS), or revascularization, but these studies do not provide guidance with regard to differences in the much more common presentation of stable chest pain (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) . Furthermore, few studies have examined the impact of such differences on provider decisions, including assessment of the likelihood of obstructive coronary artery disease (CAD) and selection of noninvasive testing (1, 5, 20) . Thus, a contemporary assessment of sex differences in the presentation and evaluation of stable outpatients without known heart disease is needed to better guide the management of women with suspected CAD.
The PROMISE (Prospective Multicenter Imaging
Study for Evaluation of Chest Pain) trial, which is a recently completed randomized trial of evaluation strategies in 10,003 symptomatic nonacute patients with suspected CAD, enrolled >5,200 women, which made it an ideal setting to explore the differences in presentation and evaluation of CAD in men versus women (21, 22) . Accordingly, we used the PROMISE dataset to compare the demographics, risk factor profiles, clinical presentation, risk estimates, choice of functional test, and test results by sex in a contemporary population of stable symptomatic outpatients with suspected CAD. We hypothesized that demographics, symptoms, and risk factor burden would differ by sex, which would, in turn, influence provider risk estimates, subsequent diagnostic evaluation choices, and noninvasive test results. (Coronary Artery Surgery Study) score (27 
METHODS

RESULTS
Among all trial patients, mean ages were 59 years (range 45 to 90) for men and 62 years (range 50 to 92 years) for women ( Table 1) . Because the inclusion criteria specified a minimum age for women of 50 years versus 45 years for men, we also examined the mean ages of only patients older than 50 years of age, and we found that, on average, women were still older. The prevalence of racial or ethnic minorities was similar between the sexes.
Women were more likely than men to have a history of hypertension, dyslipidemia, cerebrovascular or peripheral vascular disease, family history of premature CAD, depression, and a sedentary lifestyle ( Table 1) . Men were more likely than women to smoke and be overweight (BMI $25 kg/m 2 ). The prevalence of diabetes was similar in both men and women.
The most common primary presenting symptom in both sexes was chest pain reported by 73.2% of women versus 72.3% of men (p ¼ 0.30) ( Table 1) . Men were more likely than women to characterize their chest pain as "aching/dull" and "burning/pins and needles." Women were more likely than men to characterize their pain as "crushing/pressure/ squeezing/tightness." Women were more likely than men to have back pain, neck, or jaw pain, and palpitations as the primary presenting symptoms, whereas men were more likely to have fatigue and/or weakness.
The use of cardiovascular medications at baseline was common in both sexes ( Table 1) . Women were more likely than men to be taking beta blockers and diuretics; men were more likely than women to be taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, statins, and aspirin. Continued on the next page imaging stress tests (stress echocardiography or stress nuclear) for women compared with men instead of nonimaging stress tests (exercise ECG) ( Table 3) .
Among only those patients in whom an imaging stress test was selected, clinicians were 17% more likely to select stress nuclear testing for women compared with men instead of stress echocardiography ( ASCVD ¼ atherosclerotic cardiovascular disease; IQR ¼ interquartile range; other abbreviation as in Table 1 .
Hemal et al. In our study, chest pain was the most commonly exhibited symptom for both women and men, although its description differed, with women being significantly more likely to describe their pain as "crushing, pressure, squeezing, or tightness."
Although previous studies have suggested that women are more likely to present with atypical symptoms than men (5,6,7,10,14), our study demonstrated that men and women were equally likely to have atypical symptoms. Women were more likely to present with back pain, neck and/or jaw pain, and palpitations in accordance with earlier studies of ACS patients, whereas men were more likely to present with fatigue and/or weakness, which is in contrast to previous investigations (15) (16) (17) (18) (19) .
Few studies have examined sex differences in risk scores in a stable outpatient population with CI ¼ confidence interval; other abbreviation as in Table 1 .
FIGURE 2 Test Positivity Rates by Sex and Test Type
Positive (%) Among our study subjects, all of whom had a requirement for noninvasive testing, clinicians more often selected imaging stress tests in women compared with men as the functional test of choice rather than nonimaging stress tests. This preference could reflect the higher likelihood in women than men to have false positive stress ECGs (1). In addition, among those selected for stress testing with imaging, women were more likely than men to be assigned to stress nuclear echocardiography more than stress echocardiography even after adjustment. Although little direct data are available to guide this choice, nuclear testing may be more sensitive for singlevessel coronary disease, which is more commonly seen in women; however, women may be more sensitive to ionizing radiation. Published metaanalyses suggest that the diagnostic accuracy of stress echocardiography does not differ by sex and prognostic value, whereas stress nuclear studies may be less accurate in women than in men (32) (33) (34) .
Overall, women in our cohort were less likely to have a positive diagnostic test than men, which is consistent with the lower risk assigned to them by both risk scores and providers. A large number of characteristics were associated with a positive test, many of which were similar in men and women.
However, few characteristics remained associated in the multivariable analysis, and the ability to predict a positive test was limited in both men and women with only modest AUCs. Finally, the characteristics that predicted a positive test in women differed from those in men, suggesting that different relationships between the risk factor burden and the subsequent clinical pathway may be present in women and in men.
STUDY LIMITATIONS. The PROMISE trial is one of the largest contemporary, prospectively studied cohorts of symptomatic men and women without known heart disease, and as such, it provides a unique opportunity to study sex differences in this population. The diversity of expertise and settings among 193 PROMISE sites and the broad enrollment criteria make our results highly generalizable to real-world settings. Despite these strengths, there are several issues to consider when interpreting our results. We focused on the initial presentation, evaluation, referral decision making, and test results for stable outpatients with chest pain or other symptoms suggestive of CAD, but PROMISE inclusion criteria required noninvasive testing in all patients; thus, our data did not address possible differences in referral patterns for such testing, because those patients who physicians chose not to test or to send directly to invasive catheterization were specifically excluded.
However, our patient population's age, symptoms, and risk factor burden were such that all had a class I indication for noninvasive testing. Because we did not have high-sensitivity C-reactive protein data, we were unable to calculate a Reynolds risk score, which has been specifically designed for use in women (35) .
The selection process for the multivariable models that assessed the association of presentation characteristics with noninvasive test positivity were exploratory in nature and have not been validated for use on external datasets.
CONCLUSIONS
There are significant sex differences in the presentation and evaluation of symptomatic stable outpatients with suspected CAD. Women who present Abbreviations as in Table 1 . 
